Jersey City-based Character Biosciences, a company specializing in genetics-guided drug discovery and development, has announced a collaboration with Bausch + Lomb, a leading global eye health company ...

Bausch + Lomb acquired Whitecap Biosciences to develop therapies for glaucoma and geographic atrophy, aiming to improve visual outcomes. Whitecap's WB007, an alpha-2 adrenergic agonist, showed IOP ...

City Therapeutics, Inc. set to collaborate with Bausch + Lomb on the development of a novel therapy for the treatment of retinal diseases including geographic atrophy (GA). The arrangement of this ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced an affiliate ...

City Therapeutics has inked a new deal with Bausch + Lomb for a gene silencing approach to the eye disorder geographic atrophy (GA). The early-stage deal breaks down like this: City gets an ...

Pre-tax losses at the main Irish unit of eye care product firm Bausch + Lomb increased by 4.5% to $959.7m (€925m) in 2023. Accounts recently filed by Bausch + Lomb Ireland Ltd show that pre-tax ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Niklas Zennström, one of Europe’s most successful tech entrepreneurs and investors, believes the ...